Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer based in Jerusalem, Israel, covers the month of April 2021. The report, dated April 6, 2021, consists solely of a press release attached as Exhibit 99.1 and incorporated by reference. The filing is signed by Spiros Jamas, Sc.D., the Chief Executive Officer and Director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this report contains only a press release without an accompanying financial statement or earnings release, no specific financial metrics are disclosed in this document.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document serves as a vehicle to incorporate a press release but does not detail specific operational or financial changes within the text of the Form 6-K itself.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the filing incorporates a press release by reference, the content of that press release is not included in the provided text, preventing a summary of management's forward-looking statements or risk factors.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K incorporating a press release dated April 6, 2021, rather than a standalone financial report.
- No financial data (revenue, cash, debt) is present in the provided text; investors must review the attached Exhibit 99.1 for details.
- The registrant files annual reports on Form 20-F.
- The filing is incorporated by reference into Registration Statements 333-238988 and 333-239843.